What is NewDays?
NewDays operates at the intersection of artificial intelligence and behavioral health, providing a comprehensive ecosystem for cognitive wellness. The company distinguishes itself by offering a hybrid model that combines telehealth consultations with licensed cognitive clinicians and personalized, AI-driven brain exercise regimens. Its core innovation, an AI companion named Sunny, serves as a continuous engagement tool, guiding patients through therapeutic homework and monitoring progress in real-time. By digitizing the clinical pathway for cognitive health, NewDays is effectively lowering barriers to entry for specialized care, positioning itself as a disruptive force in the burgeoning digital therapeutics market. The platform's ability to synthesize clinical data with patient-specific behavioral insights allows for a highly personalized treatment experience that traditional, manual care models struggle to replicate at scale.
How much funding has NewDays raised?
NewDays has raised a total of $7M across 1 funding round:
Seed
$7M
Seed (2025): $7M with participation from Madrona Venture Group and General Catalyst
Key Investors in NewDays
Madrona Venture Group
Founded in 1995, Madrona Venture Group is a venture capitalist investment company including consumer internet, commercial software, and services.
General Catalyst
General Catalyst operates as a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages.
What's next for NewDays?
Following this major enterprise-level funding, NewDays is expected to prioritize the expansion of its clinical network and the further refinement of its AI-driven diagnostic capabilities. The strategic roadmap likely includes enhancing the cognitive modeling of the Sunny companion to support a broader range of neurological conditions. Furthermore, the company is poised to leverage this capital to pursue enterprise partnerships with healthcare systems and insurance providers, aiming to integrate its cognitive health solutions into standard care protocols. As the firm transitions from its initial development phase to a period of rapid market penetration, the focus will remain on validating clinical outcomes and demonstrating the long-term efficacy of its AI-assisted treatment model to institutional stakeholders.
See full NewDays company page
